Orano Med (previously AREVA Med) is Macrocyclics’ parent company since 2011.
Orano Med is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (²¹²Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells.
With Macrocyclics and Pharma partners, Orano Med pursues the development of effective therapies to address patients’ needs. Orano Med is the subsidiary of the Orano group.
Discover more about Orano Med at www.OranoMed.com and in our video: